iBio Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Stockholders' Equity (Narrative) (Details)

Stockholders' Equity (Narrative) (Details)											1 Months Ended		3 Months Ended				4 Months Ended	5 Months Ended	9 Months Ended	12 Months Ended
Stockholders' Equity (Narrative) (Details)	Oct. 07, 2022	Jul. 19, 2022 shares	May 09, 2022 USD ($) $ / shares shares	Oct. 31, 2021 $ / shares	Jun. 17, 2020 USD ($)	Mar. 19, 2020 USD ($) $ / shares shares	Oct. 29, 2019 $ / shares shares	Oct. 28, 2019 shares	Jun. 26, 2018 shares	Feb. 23, 2017 USD ($) shares	Sep. 30, 2021 shares	Jul. 27, 2020 USD ($) shares	Jun. 30, 2022 USD ($) $ / shares shares	Mar. 31, 2022 shares	Dec. 31, 2021 shares	Mar. 31, 2021 shares	Oct. 25, 2020 USD ($)	Nov. 25, 2020 shares	Jun. 30, 2020 USD ($) shares	Jun. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2021 USD ($) shares	Nov. 01, 2021 $ / shares shares	Jun. 20, 2018 shares
Stockholders' Equity [Line Items]
Preferred Stock, shares authorized													1,000,000							1,000,000
Preferred stock, shares outstanding (in shares)													1,000							1,000	0
Preferred stock, par value (in dollars per share) \| $ / shares													$ 0.001							$ 0.001
Common stock, shares authorized (in shares)													275,000,000							275,000,000	275,000,000
Exercise of stock options (in shares)											3,380									3,380	2,147
Exercise of warrants (in shares)																			1,162,807
Proceeds from exercise of warrants \| $																			$ 6,400,000
Shares of common stock issued for the cashless exercise of Warrants																			237,193
Cashless exercise of warrants reducing balance owed for notes payable - warrant exchange \| $																			$ 1,300,000
Costs related to the warrant exchange offset against additional paid-in capital \| $																			$ 313,000
Warrants outstanding																					0
Stockholders' Equity Note, Stock Split, Conversion Ratio	0.04
Weighted average risk-free interest rate
Stockholders' Equity [Line Items]
Fair value of the Warrant assumptions													0.23							0.23
Dividend yield
Stockholders' Equity [Line Items]
Fair value of the Warrant assumptions													0							0
Volatility
Stockholders' Equity [Line Items]
Fair value of the Warrant assumptions													136.9							136.9
Expected term (in years)
Stockholders' Equity [Line Items]
Fair value of the Warrant assumptions													4.95							4.95
College Station Investors LLC And Bryan Capital [Member]
Stockholders' Equity [Line Items]
Warrants, exercise price per share \| $ / shares																						$ 33.25
Warrants to purchase shares of Common Stock																						51,583
Series A Common Stock Purchase Warrants [Member]
Stockholders' Equity [Line Items]
Number of shares issued							1,000,000
Warrants, exercise price per share \| $ / shares							$ 5.50
Term of the warrants							2 years
Series B Common Stock Purchase Warrants [Member]
Stockholders' Equity [Line Items]
Number of shares issued							1,000,000
Warrants, exercise price per share \| $ / shares							$ 5.50
Term of the warrants							7 years
Series A Preferred Stock [Member]
Stockholders' Equity [Line Items]
Preferred stock, shares outstanding (in shares)													0							0	0
Preferred stock, par value (in dollars per share) \| $ / shares													$ 0.001							$ 0.001
Number of shares designated																							6,300
Number of common stock issued upon conversion									334,320
Series B Preferred Stock [Member]
Stockholders' Equity [Line Items]
Preferred stock, shares outstanding (in shares)													0							0	0
Preferred stock, par value (in dollars per share) \| $ / shares													$ 0.001							$ 0.001
Number of shares designated																							5,785
Number of common stock issued upon conversion									1,157,400
Series C Preferred Stock [Member]
Stockholders' Equity [Line Items]
Preferred stock, shares outstanding (in shares)													0							0	0
Preferred stock, par value (in dollars per share) \| $ / shares													$ 0.001							$ 0.001
Number of common stock issued upon conversion								902,000
iBio CMO Preferred Tracking Stock [Member]
Stockholders' Equity [Line Items]
Preferred Stock, Dividend Rate, Percentage										2.00%
Preferred Stock, Dividends Per Share, Declared \| $ / shares				$ 0
Preferred stock, shares outstanding (in shares)																						0
Dividends Payable \| $													$ 0							$ 0	$ 1,131,000
Series 2022 Convertible Preferred Stock [Member]
Stockholders' Equity [Line Items]
Proceeds from sale of shares, net of issuance cost \| $			$ 270
Preferred stock, par value (in dollars per share) \| $ / shares			$ 0.001
Number of shares issued			1,000
Number of common stock issued upon conversion		1	1
Restricted Stock Units [Member]
Stockholders' Equity [Line Items]
Shares vested													533	4,201	4,120	379
Omnibus Incentive (the 2020) Plan [Member]
Stockholders' Equity [Line Items]
Shares available for grant under the plan													32,000,000							32,000,000
Underwritten Public Offering [Member] \| Series A Preferred Stock [Member]
Stockholders' Equity [Line Items]
Number of shares issued									6,300
Underwritten Public Offering [Member] \| Series B Preferred Stock [Member]
Stockholders' Equity [Line Items]
Number of shares issued									5,785
Underwritten Public Offering [Member] \| Series C Preferred Stock [Member]
Stockholders' Equity [Line Items]
Number of shares issued								4,510
Exchange Agreement [Member] \| iBio CMO Preferred Tracking Stock [Member] \| Bioprocessing (iBio CDMO) [Member]
Stockholders' Equity [Line Items]
Stock Issued During Period, Shares, Acquisitions										1
Number of LLC interest units exchanged for each share of preferred tracking stock										29,990,000
Proceeds from sale of shares, net of issuance cost \| $										$ 13,000,000
Exchange Agreement [Member] \| iBio CMO Preferred Tracking Stock [Member] \| After Preferred Tracking Stock Exchanged for Units of Limited Liability Company Interests [Member] \| Bioprocessing (iBio CDMO) [Member]
Stockholders' Equity [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent										99.99%
Exchange Agreement [Member] \| Eastern Affiliate [Member] \| iBio CMO Preferred Tracking Stock [Member] \| After Preferred Tracking Stock Exchanged for Units of Limited Liability Company Interests [Member] \| Bioprocessing (iBio CDMO) [Member]
Stockholders' Equity [Line Items]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners										0.01%
Equity Distribution Agreement [Member] \| UBS Securities, LLC ("UBS") [Member]
Stockholders' Equity [Line Items]
Proceeds from sale of shares, net of issuance cost \| $					$ 72,000,000												$ 26,700,000
Number of shares issued																		416,359
Commission Rate					3.00%
Underwriting Discounts, Commissions and Other Offering Expenses \| $					$ 50,000
Lincoln Park Purchase Agreement [Member]
Stockholders' Equity [Line Items]
Proceeds from sale of shares, net of issuance cost \| $						$ 5,000,000						$ 6,790,000
Number of shares issued												106,921
Common stock, shares authorized (in shares)						40,000
Term of purchase agreement						36 months
Lincoln Park Purchase Agreement [Member] \| Lincoln Park Capital Fund, LLC [Member]
Stockholders' Equity [Line Items]
Proceeds from sale of shares, net of issuance cost \| $						$ 50,000,000
Term of purchase agreement						36 months
Closing price floor per share \| $ / shares						$ 0.20